MA42659A - Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp - Google Patents

Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp

Info

Publication number: MA42659A
Authority: MA; Morocco
Prior art keywords: heteraryl; parp inhibitors; derivatives used; derivatives; parp
Prior art date: 2015-08-17

Application number

MA042659A

Other languages

English (en)

Inventor

Nishant Ramniwasji Gupta

Ganesh Rajaram Jadhav

Rajender Kumar Kamboj

Navnath Popat Karche

Sanjay Pralhad Kurhade

Venkata P Palle

Neelima Sinha

Ajay Ramchandra Tilekar

Original Assignee

Lupin Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-17

Filing date

2016-08-13

Publication date

2018-06-27

2016-08-13 Application filed by Lupin Ltd filed Critical Lupin Ltd

2018-06-27 Publication of MA42659A publication Critical patent/MA42659A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

MA042659A 2015-08-17 2016-08-13 Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp MA42659A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
IN3111MU2015		2015-08-17
IN3588MU2015		2015-09-21
IN201621000832		2016-01-08
PCT/IB2016/054886 WO2017029601A1 (fr)	2015-08-17	2016-08-13	Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp

Publications (1)

Publication Number	Publication Date
MA42659A true MA42659A (fr)	2018-06-27

Family

ID=56920883

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA042659A MA42659A (fr)	2015-08-17	2016-08-13	Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp

Country Status (21)

Country	Link
US (1)	US20200101068A1 (fr)
EP (1)	EP3337802A1 (fr)
JP (1)	JP2018523679A (fr)
KR (1)	KR20180037265A (fr)
CN (1)	CN107922409A (fr)
AU (1)	AU2016308717A1 (fr)
BR (1)	BR112018002465A2 (fr)
CA (1)	CA2991232A1 (fr)
CL (1)	CL2018000338A1 (fr)
CO (1)	CO2018001268A2 (fr)
CR (1)	CR20180168A (fr)
CU (1)	CU20180019A7 (fr)
EA (1)	EA033613B1 (fr)
HK (1)	HK1255269A1 (fr)
IL (1)	IL256808A (fr)
MA (1)	MA42659A (fr)
MX (1)	MX2018001871A (fr)
PE (1)	PE20181144A1 (fr)
PH (1)	PH12018500360A1 (fr)
SV (1)	SV2018005633A (fr)
WO (1)	WO2017029601A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3151595A1 (fr)	2016-01-08	2017-07-13	Arcus Biosciences, Inc.	Modulateurs de l'ecto-5'-nucleotidase et leur utilisation
MA48594B1 (fr)	2016-12-08	2022-05-31	Hoffmann La Roche	Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a
US11045773B2 (en)	2018-08-31	2021-06-29	Pall Corporation	Salt tolerant porous medium
US10737259B2 (en)	2018-08-31	2020-08-11	Pall Corporation	Salt tolerant anion exchange medium
AU2020281410A1 (en) *	2019-05-31	2021-10-07	Haisco Pharmaceuticals Pte. Ltd.	BTK inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
US11633416B1 (en)	2020-03-06	2023-04-25	Arcus Biosciences, Inc.	Oral formulations of CD73 compounds
WO2021257857A1 (fr)	2020-06-19	2021-12-23	Incyte Corporation	Composés naphtyridinone en tant qu'inhibiteurs de jak2 v617f
WO2021257863A1 (fr)	2020-06-19	2021-12-23	Incyte Corporation	Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
US11767323B2 (en)	2020-07-02	2023-09-26	Incyte Corporation	Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022006457A1 (fr)	2020-07-02	2022-01-06	Incyte Corporation	Composés d'urée tricycliques en tant qu'inhibiteurs de v617f de jak2
CN112062770A (zh) *	2020-08-21	2020-12-11	台州学院	一种稠环二氢吡啶酮的制备方法
WO2022046989A1 (fr)	2020-08-27	2022-03-03	Incyte Corporation	Composés d'urée tricycliques en tant qu'inhibiteurs de v617f de jak2
US11919908B2 (en)	2020-12-21	2024-03-05	Incyte Corporation	Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
WO2022182839A1 (fr)	2021-02-25	2022-09-01	Incyte Corporation	Lactames spirocycliques utilisés comme inhibiteurs du v617f de jak2
CN116867784A (zh) *	2021-04-23	2023-10-10	成都百裕制药股份有限公司	吡啶衍生物及其在医药上的应用
CN120058698A (zh) *	2021-10-01	2025-05-30	新特拉有限公司	氮杂环丁烷和吡咯烷parp1抑制剂及其用途
IL320829A (en)	2022-01-21	2025-07-01	Xinthera Inc	PARP1 inhibitors and their uses
EP4444305A2 (fr) *	2022-02-16	2024-10-16	Duke Street Bio Limited	Composé pharmaceutique
JP2025509672A (ja)	2022-03-17	2025-04-11	インサイト・コーポレイション	Ｊａｋ２ｖ６１７ｆ阻害剤としての三環式尿素化合物
PT4355749T (pt)	2022-04-28	2025-08-13	Xinthera Inc	Inibidores tricíclicos da parp1 e suas utilizações
WO2024050370A1 (fr) *	2022-08-30	2024-03-07	1Cbio, Inc.	Composés hétérocycliques et leurs procédés d'utilisation
TW202508595A (zh)	2023-05-04	2025-03-01	美商銳新醫藥公司	用於ｒａｓ相關疾病或病症之組合療法
GB2630970A (en) *	2023-06-15	2024-12-18	Duke Street Bio Ltd	PARP1 inhibitor compounds
WO2025034702A1 (fr)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
GB2634233A (en) *	2023-10-02	2025-04-09	Duke Street Bio Ltd	PARP1 inhibitor compounds
GB2634228A (en) *	2023-10-02	2025-04-09	Duke Street Bio Ltd	PARP1 inhibitor compounds
WO2025080946A2 (fr)	2023-10-12	2025-04-17	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2025091346A1 (fr) *	2023-11-01	2025-05-08	Suzhou Eoc Medical Research Co., Ltd.	Inhibiteurs de parp et leurs utilisations
WO2025171296A1 (fr)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2025217307A1 (fr)	2024-04-09	2025-10-16	Revolution Medicines, Inc.	Procédés de prédiction de la réponse à un inhibiteur de ras(on) et polythérapies
WO2025240847A1 (fr)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Inhibiteurs de ras

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US5019369A (en)	1984-10-22	1991-05-28	Vestar, Inc.	Method of targeting tumors in humans
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
EP1029851B1 (fr)	1997-10-14	2005-04-20	Mitsubishi Pharma Corporation	Composes de piperazine et utilisation medicale desdits composes
BR0115062A (pt)	2000-10-30	2004-02-17	Kudos Pharm Ltd	Derivados de ftalazinona
US6664269B2 (en) *	2001-05-08	2003-12-16	Maybridge Plc	Isoquinolinone derivatives
WO2002094790A1 (fr) *	2001-05-23	2002-11-28	Mitsubishi Pharma Corporation	Compose heterocyclique condense et son utilisation medicale
AUPR975601A0 (en)	2001-12-24	2002-01-31	Fujisawa Pharmaceutical Co., Ltd.	Quinazolinone derivatives
AUPS019702A0 (en)	2002-01-29	2002-02-21	Fujisawa Pharmaceutical Co., Ltd.	Condensed heterocyclic compounds
DE10313319A1 (de)	2003-03-25	2004-10-07	Basf Ag	Verfahren zur Hydroformylierung
MX2011005800A (es)	2008-12-02	2011-06-20	Glaxo Group Ltd	Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos.
US20120077814A1 (en)	2010-09-10	2012-03-29	Zhong Wang	Sulfonamide, sulfamate, and sulfamothioate derivatives
US8883789B2 (en)	2011-12-14	2014-11-11	Boehringer Ingelheim International Gmbh	Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
WO2013143663A1 (fr)	2012-03-28	2013-10-03	Merck Patent Gmbh	Dérivés bicycliques de pyrazinone
EP2870140B8 (fr) *	2012-07-09	2016-09-28	Lupin Limited	Derives de tetrahydroquinazolinone comme inhibiteurs de parp
WO2015200677A2 (fr)	2014-06-25	2015-12-30	Epizyme, Inc.	Inhibiteurs de prmt5 et leurs utilisations
WO2016012956A1 (fr) *	2014-07-24	2016-01-28	Lupin Limited	Dérivés d'isoquinolinone utilisés en tant qu'inhibiteurs de parp

2016
- 2016-08-13 WO PCT/IB2016/054886 patent/WO2017029601A1/fr not_active Ceased
- 2016-08-13 US US15/746,967 patent/US20200101068A1/en not_active Abandoned
- 2016-08-13 CA CA2991232A patent/CA2991232A1/fr not_active Abandoned
- 2016-08-13 EA EA201890473A patent/EA033613B1/ru not_active IP Right Cessation
- 2016-08-13 PE PE2018000206A patent/PE20181144A1/es unknown
- 2016-08-13 CN CN201680047044.7A patent/CN107922409A/zh active Pending
- 2016-08-13 KR KR1020187006982A patent/KR20180037265A/ko not_active Withdrawn
- 2016-08-13 HK HK18114427.4A patent/HK1255269A1/zh unknown
- 2016-08-13 AU AU2016308717A patent/AU2016308717A1/en not_active Abandoned
- 2016-08-13 CU CUP2018000019A patent/CU20180019A7/xx unknown
- 2016-08-13 MX MX2018001871A patent/MX2018001871A/es unknown
- 2016-08-13 MA MA042659A patent/MA42659A/fr unknown
- 2016-08-13 EP EP16763958.2A patent/EP3337802A1/fr not_active Withdrawn
- 2016-08-13 BR BR112018002465A patent/BR112018002465A2/pt not_active Application Discontinuation
- 2016-08-13 JP JP2018508645A patent/JP2018523679A/ja active Pending
- 2016-08-13 CR CR20180168A patent/CR20180168A/es unknown
2018
- 2018-01-09 IL IL256808A patent/IL256808A/en unknown
- 2018-02-06 CL CL2018000338A patent/CL2018000338A1/es unknown
- 2018-02-07 CO CONC2018/0001268A patent/CO2018001268A2/es unknown
- 2018-02-15 PH PH12018500360A patent/PH12018500360A1/en unknown
- 2018-02-16 SV SV2018005633A patent/SV2018005633A/es unknown

Also Published As

Publication number	Publication date
EP3337802A1 (fr)	2018-06-27
MX2018001871A (es)	2018-05-28
KR20180037265A (ko)	2018-04-11
PE20181144A1 (es)	2018-07-17
HK1255269A1 (zh)	2019-08-09
AU2016308717A1 (en)	2018-01-25
SV2018005633A (es)	2018-04-11
CA2991232A1 (fr)	2017-02-23
CR20180168A (es)	2018-06-27
EA033613B1 (ru)	2019-11-08
CL2018000338A1 (es)	2018-07-20
US20200101068A1 (en)	2020-04-02
CU20180019A7 (es)	2018-06-05
CN107922409A (zh)	2018-04-17
EA201890473A1 (ru)	2018-07-31
JP2018523679A (ja)	2018-08-23
CO2018001268A2 (es)	2018-06-20
WO2017029601A1 (fr)	2017-02-23
BR112018002465A2 (pt)	2018-09-18
PH12018500360A1 (en)	2018-08-29
IL256808A (en)	2018-03-29

Publication	Publication Date	Title
MA42659A (fr)	2018-06-27	Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA47125A (fr)	2021-04-28	Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA47120A (fr)	2021-04-28	Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA45244A (fr)	2019-04-17	Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA46981A (fr)	2019-10-09	Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
EP3416964A4 (fr)	2019-09-18	Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA43169A (fr)	2018-09-12	Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA47123A (fr)	2021-03-17	Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA40774A (fr)	2017-08-08	Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA41140A (fr)	2017-10-17	Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA47013A (fr)	2018-08-29	Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA48994A (fr)	2020-02-05	Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA47460A (fr)	2019-12-18	Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA47086A (fr)	2021-04-28	Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
MA46339A (fr)	2019-08-07	Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA51438A (fr)	2021-04-14	Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA42990A (fr)	2021-03-31	Composés utiles en tant qu'immunomodulateurs
MA55194A (fr)	2022-05-04	Composés hétérocycliques en tant qu'immunomodulateurs
MA41551A (fr)	2017-12-26	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA51431A (fr)	2021-04-07	Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA45153A (fr)	2021-04-07	Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
EP3733671A4 (fr)	2021-06-09	Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA40940A (fr)	2017-09-19	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3386981A4 (fr)	2019-06-19	Hétérocycles utiles en tant qu'agents anticancereux
MA54567A (fr)	2021-10-27	Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma